Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 20/20 | 0.65 |
| ▸ | PKD1 | P98161 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929431 | 0.87 | MAP3K14 (0.62) | MAP3K14PKD1 | |
| SCHEMBL20929430 | 0.87 | MAP3K14 (0.62) | MAP3K14PKD1 | |
| SCHEMBL19899366 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL19899365 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL29599383 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL20929168 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL19899371 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL19899364 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL29600492 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 | |
| SCHEMBL29600148 | 0.86 | MAP3K14 (0.64) | MAP3K14PKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654824-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190119246-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654824-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | NFKB2, NFKBIA, NFKB1 | MAP3K14 699/4885PKD1 2538/4885 |
| US-20190119246-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | NFKB2, NFKBIA, NFKB1 | MAP3K14 699/4885PKD1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.